New therapeutic approaches to mendelian disorders.

@article{Dietz2010NewTA,
  title={New therapeutic approaches to mendelian disorders.},
  author={Harry C. Dietz},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 9},
  pages={
          852-63
        }
}
  • Harry C. Dietz
  • Published in
    The New England journal of…
     2010
  • Medicine
    • Thanks to the power of a method to identify etiologic mutations (and hence “causative” genes) in mendelian disease, the molecular mechanisms that give rise to many such diseases are now known. This knowledge has fueled new therapeutic approaches, which are reviewed in this article, the third in the Genomic Medicine series. 
    View PDF
    49 Citations
    19 Cite Background
    1 Cite Methods
    2
    Twitter Mentions

    Figures and Topics from this paper.

    Figures

    Explore Further: Topics Discussed in This Paper

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 49 CITATIONS

    DGAT-onco: A powerful method to detect oncogenes by integrating differential mutational analysis and functional impacts of somatic mutations

    An overview of the genetic basis of cardiovascular disease

    Mutation update for the SATB 2 gene

    VIEW 2 EXCERPTS
    CITES BACKGROUND

    Pathophysiology of Niemann-Pick Type C and Fabry diseases with Emphasis on Membrane Composition and Protein Trafficking

    Characteristics of rare diseases

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Transcriptome profile of the human placenta

    VIEW 2 EXCERPTS
    CITES BACKGROUND

    Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases

    Combined mitral valve replacement associated with the Bentall procedure, diaphragmatic hernia repair and reconstruction of the pectus excavatum in a 26-year-old patient with Marfan syndrome

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Cutaneous Manifestations of Mucopolysaccharidoses.

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 74 REFERENCES

    Circulating transforming growth factor-beta in Marfan syndrome.

    Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells.

    Drug development and the cellular quality control system.

    Func - tional basis of protection against age - related macular degeneration conferred by a common polymorphism in complement factor B

    • T Montes, A Tortajada, CL Harris
    • Proc Natl Acad Sci U S A
    • 2009

    Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

    Goal-oriented therapy with miglustat in Gaucher disease.

    Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year.

    Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression.

    Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.

    Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice.

    • Bo Wu, Yongfu Li, +3 authors Qi Lu
    • Biology, Medicine
    • Molecular therapy : the journal of the American Society of Gene Therapy
    • 2009